Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
about
The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycleAuto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survivalBiokinetically-based in vitro cardiotoxicity of residual oil fly ash: hazard identification and mechanisms of injuryActivation of JAK-STAT and nitric oxide signaling as a mechanism for donor heart dysfunctionWild-type p53-induced Phosphatase 1 Deficiency Exacerbates Myocardial Infarction-induced Ischemic Injury.Effects of interleukin-33 on cardiac fibroblast gene expression and activity.Characterization of the regulatory mechanisms of activating transcription factor 3 by hypertrophic stimuli in rat cardiomyocytesInhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation.Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.STAT subtype specificity and ischemic preconditioning in mice: is STAT-3 enough?Cardiac-Specific SOCS3 Deletion Prevents In Vivo Myocardial Ischemia Reperfusion Injury through Sustained Activation of Cardioprotective Signaling Molecules.Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias.Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart.Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer.Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathwayActivation of AP-1 contributes to the beta-adrenoceptor-mediated myocardial induction of interleukin-6.Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion.JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.The varying faces of IL-6: From cardiac protection to cardiac failure.Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes.Critical Roles of STAT3 in β-Adrenergic Functions in the HeartHerbal Supplement Ameliorates Cardiac Hypertrophy in Rats with CCl(4)-Induced Liver CirrhosisRole of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspectsAdipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2.Integrated microRNA‑gene analysis of coronary artery disease based on miRNA and gene expression profiles.Regulating RISK: a role for JAK-STAT signaling in postconditioning?Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophyGene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity.Pregnancy as a cardiac stress modelExtracellular matrix roles during cardiac repair.Cardiotrophin-1 in hypertensive heart disease.The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response.SOCS3: A novel therapeutic target for cardioprotection.Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers.Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients.Understanding STAT3 signaling in cardiac ischemia.
P2860
Q24301823-35DA560C-631F-4FF7-9A07-8E0EEF4689CAQ28577251-137423B6-B0CC-4DB6-9841-57E594CDD8CAQ28950835-AD121F56-3F10-416A-B91C-E3A1E2494DA7Q33708028-9F6026DC-F949-4D56-AE1F-7AD5D18F4B5FQ33755606-150DC2EA-789A-47CB-9A6A-25D55AC89BFDQ33765909-480D7671-3C40-4320-BE75-59E29B72D375Q34066667-48A52101-5609-4D93-8718-32371C5BF804Q34196423-1B5C151A-5BA0-4308-9222-FF404B6FBB63Q34360215-E30601F2-4EB3-423B-9DA0-FC206FFD4017Q34600271-A4786F2E-20B5-4BFC-8ADC-6215E2983475Q35641335-C454EA8F-C413-47A1-8D3E-B76D10881260Q35660566-AAB8C46A-DDE9-4457-AA8D-9F9008100C6CQ35710032-CB2E822D-CFA7-49FB-8A64-B1A7145CA042Q35723859-BF6C6908-755D-4856-81DE-067333CB861CQ35759017-7975AA96-9BD3-4593-8F71-DEB0535FBEE0Q35770447-458557E1-AB76-4F13-A1BE-566E94E1BDCCQ35794521-6B8E85CD-940B-4EAC-AA7A-7C1782A25307Q36072891-70A3DF41-76F4-44F3-B1B7-31243976EB27Q36099739-0C732B2A-0E12-43D2-89AA-838A430ED495Q36176015-1E2612AF-44DE-4338-A086-FB7FF23A664DQ36368339-51D5FB9B-3847-4CCA-BED0-335F0B712A0CQ36392857-BD525BA3-ECEB-4E76-9A17-FE8258654A1AQ36421513-27D0CED4-1B8C-40E8-A3AD-383D4E9597BFQ36453305-66B4B65D-C527-414E-B6B8-B95AFEDE54D1Q36497007-F8CDB925-812D-4714-BB08-CEC4B61DAA46Q36650882-D86A0E94-784B-457F-8DF0-79524663CF75Q36722119-733C8653-FAB7-4B6F-BA6B-9A12DA746994Q36995201-E4968C8A-C51E-4469-806C-7D126B417FA9Q37066737-12CBC033-B30E-42D6-A036-950DA9E19977Q37264079-2DD0437A-466C-41DB-B881-545EDF76A82FQ37344100-5DB40916-6BF4-4539-88A3-40E704C887E3Q37412473-B895C62A-2577-474B-AF23-AE4CBF80122BQ37615822-7A4ED8C3-A76E-45C1-9D81-2BD1B43E4B9FQ37776560-B2FCA0F2-CA52-4DA4-AC4D-ECC283549646Q37993729-EA5CBAB0-BDAE-432C-BD6D-2D3557445319Q38140886-F70EEA14-0FDD-4846-A4E3-025C2EDCDD12Q38140895-329DD459-0AD9-4E76-838E-35B0C42FA201Q38177341-D52B49FC-2BDE-4CBB-B58A-C821526DC39AQ38510554-A6FCAD36-9001-49C5-9F86-A8CE176997B9Q38790211-2E19D650-2323-493D-8564-2CFC28C82389
P2860
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@ast
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en-gb
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@nl
type
label
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@ast
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en-gb
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@nl
prefLabel
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@ast
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en-gb
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@nl
P921
P3181
P1476
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis
@en
P2093
D Hilfiker-Kleiner
P2888
P304
P3181
P356
10.1007/S00395-007-0658-Z
P407
P577
2007-07-01T00:00:00Z
P5875
P6179
1014217363